Adaptation to chronic MG132 reduces oxidative toxicity by a CuZnSOD-dependent mechanism

J Neurochem. 2008 Jul;106(2):860-74. doi: 10.1111/j.1471-4159.2008.05459.x. Epub 2008 May 3.

Abstract

To study whether and how cells adapt to chronic cellular stress, we exposed PC12 cells to the proteasome inhibitor MG132 (0.1 microM) for 2 weeks and longer. This treatment reduced chymotrypsin-like proteasome activity by 47% and was associated with protection against both 6-hydroxydopamine (6-OHDA; 100 microM) and higher dose MG132 (40 microM). Protection developed slowly over the course of the first 2 weeks of exposure and was chronic thereafter. There was no change in total GSH levels after MG132. Buthionine sulfoximine (100 microM) reduced GSH levels by 60%, but exacerbated 6-OHDA toxicity to the same extent in both MG132-treated and control cells and failed to reduce MG132-induced protection. Chronic MG132 resulted in elevated antioxidant proteins CuZn superoxide dismutase (SOD; +55%), MnSOD (+21%), and catalase (+15%), as well as chaperone heat-shock protein 70 (+42%). Examination of SOD enzyme activity revealed higher levels of CuZnSOD (+40%), with no change in MnSOD. We further assessed the mechanism of protection by reducing CuZnSOD levels with two independent siRNA sequences, both of which successfully attenuated protection against 6-OHDA. Previous reports suggested that artificial over-expression of CuZnSOD in dopaminergic cells is protective. Our data complement such observations, revealing that dopaminergic cells are also able to use endogenous CuZnSOD in self-defensive adaptations to chronic stress, and that they can even do so in the face of extensive GSH loss.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adaptation, Biological / drug effects*
  • Adrenergic Agents / pharmacology
  • Animals
  • Buthionine Sulfoximine / pharmacology
  • Catalase / metabolism
  • Cell Survival / drug effects
  • Cysteine Proteinase Inhibitors / pharmacology*
  • Dopamine / metabolism
  • Enzyme Inhibitors / pharmacology
  • Glutathione / metabolism
  • Leupeptins / pharmacology*
  • Oxidative Stress / drug effects*
  • Oxidative Stress / physiology*
  • Oxidopamine / pharmacology
  • PC12 Cells / drug effects
  • Proteasome Endopeptidase Complex / metabolism
  • RNA, Small Interfering / pharmacology
  • Rats
  • Superoxide Dismutase / physiology*
  • Tyrosine 3-Monooxygenase / metabolism

Substances

  • Adrenergic Agents
  • Cysteine Proteinase Inhibitors
  • Enzyme Inhibitors
  • Leupeptins
  • RNA, Small Interfering
  • Buthionine Sulfoximine
  • Oxidopamine
  • Catalase
  • Tyrosine 3-Monooxygenase
  • Superoxide Dismutase
  • Proteasome Endopeptidase Complex
  • Glutathione
  • benzyloxycarbonylleucyl-leucyl-leucine aldehyde
  • Dopamine